Poly Medicure Ltd Reports 21% Revenue Growth in FY 2025; Q4 Core EBITDA Margin at 27.1%

Poly Medicure Ltd, a leading Medical Device company, announced its audited consolidated and standalone financial results for the quarter and year ended on March 31st, 2025. The company reported a consolidated revenue growth of 21% and 17% for the full year and quarter ended March 31, 2025, respectively. The EBITDA grew by 26.6% and 23.8% for the full year and quarter ended March 31, 2025, respectively. The PAT grew by 31.1% and 34.3% for the full year and quarter ended March 31, 2025, respectively. The company's renal division continues to gain market share in the domestic market with revenue growth of 69% and 60% in Q4 and FY2025 period respectively. The company incurred a CAPEX of Rs. 325crs in FY 25 and the balance sheet position remains strong with liquidity position of Rs. 1220crs as at March 25. The company believes that India MedTech sector is well-positioned to benefit from the ongoing geopolitical situation on a longer term basis.